MANNELLI, FRANCESCO
MANNELLI, FRANCESCO
Medicina Sperimentale e Clinica
A case of aleukemic mast cell leukemia with an underlying myeloproliferative neoplasm: Morphological and molecular characteristics of a highly aggressive disease
2020 Loscocco G.G.; Mannelli F.; Mannelli L.; Vergoni F.; Gesullo F.; Rotunno G.; Guglielmelli P.; Vannucchi A.M.
A life-threatening ruxolitinib discontinuation syndrome
2017 Coltro, Giacomo; Mannelli, Francesco; Guglielmelli, Paola; Pacilli, Annalisa; Bosi, Alberto; Vannucchi, Alessandro Maria
A systematic analysis of bone marrow cells by flow cytometry defines a specific phenotypic profile beyond GPI deficiency in paroxysmal nocturnal hemoglobinuria.
2013 Mannelli F; Bencini S; Peruzzi B; Cutini I; Sanna A; Benelli M; Magi A; Gianfaldoni G; Rotunno G; Carrai V; Gelli AM; Valle V; Santini V; Notaro R; Luzzatto L; Bosi A.
A systematic analysis of bone marrow cells by flow cytometry defines a specific phenotypic profile beyond GPI deficiency in paroxysmal nocturnal hemoglobinuria.
2012 Mannelli F;Bencini S;Peruzzi B;Cutini I;Sanna A;Benelli M;Magi A;Gianfaldoni G;Rotunno G;Carrai V;Gelli AM;Valle V;Santini V;Notaro R;Luzzatto L;Bosi A
AMELIORATE: early intensification in FLT3-mutated acute myeloid leukemia based on peripheral blast clearance – MYNERVA-GIMEMA AML1919 trial
2021 Mannelli, Francesco; Gianfaldoni, Giacomo; Guglielmelli, Paola; Buccisano, Francesco; Caporale, Roberto; Chiarini, Marco; Rossi, Giuseppe; Venditti, Adriano; Fazi, Paola; Crea, Enrico; Piciocchi, Alfonso; Voso, Maria Teresa; Vignetti, Marco; Amadori, Sergio; Vannucchi, Alessandro Maria
Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a real-life setting: An Italian MYNERVA Project
2023 Coltro, Giacomo; Sant'Antonio, Emanuela; Palumbo, Giuseppe A; Mannelli, Francesco; De Stefano, Valerio; Ruggeri, Marco; Elli, Elena M; Zanotti, Roberta; Borsani, Oscar; Bertozzi, Irene; Duminuco, Andrea; Betti, Silvia; Carli, Giuseppe; Cavalca, Fabrizio; Tanasi, Ilaria; Rumi, Elisa; Randi, Maria L; Garibaldi, Bruno; Loscocco, Giuseppe G; Guglielmelli, Paola; Vannucchi, Alessandro M
ASXL1 mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera
2022 Guglielmelli, Paola; Coltro, Giacomo; Mannelli, Francesco; Rotunno, Giada; Loscocco, Giuseppe G; Mannarelli, Carmela; Maccari, Chiara; Paoli, Chiara; Romagnoli, Simone; Bartalucci, Niccolò; Vannucchi, Alessandro M
Atypical acute leukemia early after liver transplantation.
2009 Mannelli, F; De Simone, P; Gianfaldoni, G; Nozzoli, C; Filipponi, F; Bosi, Alberto
Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study.
2012 Pagano L;Valentini CG;Pulsoni A;Fisogni S;Carluccio P;Mannelli F;Lunghi M;Pica G;Onida F;Cattaneo C;Piccaluga P;Di Bona E;Todisco E;Musto P;Spadea A;D'Arco A;Pileri S;Leone G;Amadori S;Facchetti F
BRAFV600E mutation in the wrong place: a case of concomitant polycythemia vera, hairy cell leukemia, and thyroid adenoma
2021 Loscocco G.G.; Rotunno G.; Mannelli L.; Mannelli F.; Vergoni F.; Guglielmelli P.; Vannucchi A.M.
CD20 expression has no prognostic role in Philadelphia-negativeB-precursor acute lymphoblastic leukemia: new insights from the molecularstudy of minimal residual disease.
2011 Mannelli F;Gianfaldoni G;Intermesoli T;Cattaneo C;Borlenghi E;Cortelazzo S;Cavattoni I;Pogliani EM;Fumagalli M;Angelucci E;Romani C;Ciceri F;Corti C;Scattolin AM;Cortelezzi A;Mattei D;Audisio E;Spinelli O;Oldani E;Bosi A;Rambaldi A;Bassan R
CEBPA-double-mutated acute myeloid leukemia displays a unique phenotypic profile: a reliable screening method and insight into biological features.
2017 Mannelli, F; Ponziani, V; Bencini, S; Bonetti, Mi; Benelli, M; Cutini, I; Gianfaldoni, G; Scappini, B; Pancani, F; Piccini, M; Rondelli, T; Caporale, R; Gelli, Am; Peruzzi, B; Chiarini, M; Borlenghi, E; Spinelli, O; Giupponi, D; Zanghì, P; Bassan, R; Rambaldi, A; Rossi, G; Bosi, A
Characteristics and clinical correlates of NFE2 mutations in chronic Myeloproliferative neoplasms
2020 Guglielmelli P.; Pacilli A.; Coltro G.; Mannelli F.; Mannelli L.; Contini E.; Rotunno G.; Bartalucci N.; Fiaccabrino S.; Sordi B.; Loscocco G.G.; Paoli C.; Vannucchi A.M.
Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00.
2010 Bassan R;Rossi G;Pogliani EM;Di Bona E;Angelucci E;Cavattoni I;Lambertenghi-Deliliers G;Mannelli F;Levis A;Ciceri F;Mattei D;Borlenghi E;Terruzzi E;Borghero C;Romani C;Spinelli O;Tosi M;Oldani E;Intermesoli T;Rambaldi A
Chronic relapsing thrombotic thrombocytopenic purpura succesfully treated with rituximab: case report
2005 E. ANTONIOLI; A. VANNUCCHI; A. BOSI; G. GIANFALDONI; F. MANNELLI
Chronic relapsing thrombotic thrombocytopenic purpura successfully treated with rituximab: case report.
2005 Gianfaldoni, G; Antonioli, E; Mannelli, F; Vannucchi, Am; Bosi, A.
Clearance of leukaemic blasts from peripheral blood during standard induction treatment predicts the bone marrow response in acute myeloid leukaemia: a pilot study.
2006 GIANFALDONI G; MANNELLI F; M. BACCINI; ANTONIOLI E; LEONI F; BOSI A
Clinical, Molecular, and Histopathological Correlates in a Series of 24 Consecutive Cases of Suspected Myeloproliferative Neoplasms with a JAK2V617F Variant Allele Frequency≤ 1%
2022 Loscocco GG, Santi R, Mannarelli C, Mannelli F, Gesullo F, Coltro G, Guglielmelli P, Gianelli U, Vannucchi AM
Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study
2021 Vannucchi A.M.; Sordi B.; Morettini A.; Nozzoli C.; Poggesi L.; Pieralli F.; Bartoloni A.; Atanasio A.; Miselli F.; Paoli C.; Loscocco G.G.; Fanelli A.; Para O.; Berni A.; Tassinari I.; Zammarchi L.; Maggi L.; Mazzoni A.; Scotti V.; Falchetti G.; Malandrino D.; Luise F.; Millotti G.; Bencini S.; Capone M.; Piccinni M.P.; Annunziato F.; Guglielmelli P.; Mannelli F.; Coltro G.; Fantoni D.; Borella M.; Ravenda E.; Peruzzi B.; Caporale R.; Cosmi L.; Liotta F.; Lombardelli L.; Logiodice F.; Vanni A.; Salvati L.; Lazzeri C.; Bonizzoli M.; Peris A.; Cianchi G.; Bosi A.; Pucatti M.; Fontanari P.; Benemei S.; MatucciCerinic M.; Turco L.
Concomitant JAK2 mutated myeloproliferative neoplasms and hereditary hemochromatosis
2022 Loscocco, Giuseppe G; Santi, Raffaella; Carrai, Valentina; Coltro, Giacomo; Mannelli, Francesco; Guglielmelli, Paola; Vannucchi, Alessandro M
| Titolo | Data di pubblicazione | Autore(i) | File |
|---|---|---|---|
| A case of aleukemic mast cell leukemia with an underlying myeloproliferative neoplasm: Morphological and molecular characteristics of a highly aggressive disease | 2020 | Loscocco G.G.; Mannelli F.; Mannelli L.; Vergoni F.; Gesullo F.; Rotunno G.; Guglielmelli P.; Vannucchi A.M. | |
| A life-threatening ruxolitinib discontinuation syndrome | 2017 | Coltro, Giacomo; Mannelli, Francesco; Guglielmelli, Paola; Pacilli, Annalisa; Bosi, Alberto; Vannucchi, Alessandro Maria | |
| A systematic analysis of bone marrow cells by flow cytometry defines a specific phenotypic profile beyond GPI deficiency in paroxysmal nocturnal hemoglobinuria. | 2013 | Mannelli F; Bencini S; Peruzzi B; Cutini I; Sanna A; Benelli M; Magi A; Gianfaldoni G; Rotunno G; Carrai V; Gelli AM; Valle V; Santini V; Notaro R; Luzzatto L; Bosi A. | |
| A systematic analysis of bone marrow cells by flow cytometry defines a specific phenotypic profile beyond GPI deficiency in paroxysmal nocturnal hemoglobinuria. | 2012 | Mannelli F;Bencini S;Peruzzi B;Cutini I;Sanna A;Benelli M;Magi A;Gianfaldoni G;Rotunno G;Carrai V;Gelli AM;Valle V;Santini V;Notaro R;Luzzatto L;Bosi A | |
| AMELIORATE: early intensification in FLT3-mutated acute myeloid leukemia based on peripheral blast clearance – MYNERVA-GIMEMA AML1919 trial | 2021 | Mannelli, Francesco; Gianfaldoni, Giacomo; Guglielmelli, Paola; Buccisano, Francesco; Caporale, Roberto; Chiarini, Marco; Rossi, Giuseppe; Venditti, Adriano; Fazi, Paola; Crea, Enrico; Piciocchi, Alfonso; Voso, Maria Teresa; Vignetti, Marco; Amadori, Sergio; Vannucchi, Alessandro Maria | |
| Assessment of the efficacy and tolerability of ruxolitinib for the treatment of myelofibrosis patients in a real-life setting: An Italian MYNERVA Project | 2023 | Coltro, Giacomo; Sant'Antonio, Emanuela; Palumbo, Giuseppe A; Mannelli, Francesco; De Stefano, Valerio; Ruggeri, Marco; Elli, Elena M; Zanotti, Roberta; Borsani, Oscar; Bertozzi, Irene; Duminuco, Andrea; Betti, Silvia; Carli, Giuseppe; Cavalca, Fabrizio; Tanasi, Ilaria; Rumi, Elisa; Randi, Maria L; Garibaldi, Bruno; Loscocco, Giuseppe G; Guglielmelli, Paola; Vannucchi, Alessandro M | |
| ASXL1 mutations are prognostically significant in PMF, but not MF following essential thrombocythemia or polycythemia vera | 2022 | Guglielmelli, Paola; Coltro, Giacomo; Mannelli, Francesco; Rotunno, Giada; Loscocco, Giuseppe G; Mannarelli, Carmela; Maccari, Chiara; Paoli, Chiara; Romagnoli, Simone; Bartalucci, Niccolò; Vannucchi, Alessandro M | |
| Atypical acute leukemia early after liver transplantation. | 2009 | Mannelli, F; De Simone, P; Gianfaldoni, G; Nozzoli, C; Filipponi, F; Bosi, Alberto | |
| Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study. | 2012 | Pagano L;Valentini CG;Pulsoni A;Fisogni S;Carluccio P;Mannelli F;Lunghi M;Pica G;Onida F;Cattaneo C;Piccaluga P;Di Bona E;Todisco E;Musto P;Spadea A;D'Arco A;Pileri S;Leone G;Amadori S;Facchetti F | |
| BRAFV600E mutation in the wrong place: a case of concomitant polycythemia vera, hairy cell leukemia, and thyroid adenoma | 2021 | Loscocco G.G.; Rotunno G.; Mannelli L.; Mannelli F.; Vergoni F.; Guglielmelli P.; Vannucchi A.M. | |
| CD20 expression has no prognostic role in Philadelphia-negativeB-precursor acute lymphoblastic leukemia: new insights from the molecularstudy of minimal residual disease. | 2011 | Mannelli F;Gianfaldoni G;Intermesoli T;Cattaneo C;Borlenghi E;Cortelazzo S;Cavattoni I;Pogliani EM;Fumagalli M;Angelucci E;Romani C;Ciceri F;Corti C;Scattolin AM;Cortelezzi A;Mattei D;Audisio E;Spinelli O;Oldani E;Bosi A;Rambaldi A;Bassan R | |
| CEBPA-double-mutated acute myeloid leukemia displays a unique phenotypic profile: a reliable screening method and insight into biological features. | 2017 | Mannelli, F; Ponziani, V; Bencini, S; Bonetti, Mi; Benelli, M; Cutini, I; Gianfaldoni, G; Scappini, B; Pancani, F; Piccini, M; Rondelli, T; Caporale, R; Gelli, Am; Peruzzi, B; Chiarini, M; Borlenghi, E; Spinelli, O; Giupponi, D; Zanghì, P; Bassan, R; Rambaldi, A; Rossi, G; Bosi, A | |
| Characteristics and clinical correlates of NFE2 mutations in chronic Myeloproliferative neoplasms | 2020 | Guglielmelli P.; Pacilli A.; Coltro G.; Mannelli F.; Mannelli L.; Contini E.; Rotunno G.; Bartalucci N.; Fiaccabrino S.; Sordi B.; Loscocco G.G.; Paoli C.; Vannucchi A.M. | |
| Chemotherapy-phased imatinib pulses improve long-term outcome of adult patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: Northern Italy Leukemia Group protocol 09/00. | 2010 | Bassan R;Rossi G;Pogliani EM;Di Bona E;Angelucci E;Cavattoni I;Lambertenghi-Deliliers G;Mannelli F;Levis A;Ciceri F;Mattei D;Borlenghi E;Terruzzi E;Borghero C;Romani C;Spinelli O;Tosi M;Oldani E;Intermesoli T;Rambaldi A | |
| Chronic relapsing thrombotic thrombocytopenic purpura succesfully treated with rituximab: case report | 2005 | E. ANTONIOLI; A. VANNUCCHI; A. BOSI; G. GIANFALDONI; F. MANNELLI | |
| Chronic relapsing thrombotic thrombocytopenic purpura successfully treated with rituximab: case report. | 2005 | Gianfaldoni, G; Antonioli, E; Mannelli, F; Vannucchi, Am; Bosi, A. | |
| Clearance of leukaemic blasts from peripheral blood during standard induction treatment predicts the bone marrow response in acute myeloid leukaemia: a pilot study. | 2006 | GIANFALDONI G; MANNELLI F; M. BACCINI; ANTONIOLI E; LEONI F; BOSI A | |
| Clinical, Molecular, and Histopathological Correlates in a Series of 24 Consecutive Cases of Suspected Myeloproliferative Neoplasms with a JAK2V617F Variant Allele Frequency≤ 1% | 2022 | Loscocco GG, Santi R, Mannarelli C, Mannelli F, Gesullo F, Coltro G, Guglielmelli P, Gianelli U, Vannucchi AM | |
| Compassionate use of JAK1/2 inhibitor ruxolitinib for severe COVID-19: a prospective observational study | 2021 | Vannucchi A.M.; Sordi B.; Morettini A.; Nozzoli C.; Poggesi L.; Pieralli F.; Bartoloni A.; Atanasio A.; Miselli F.; Paoli C.; Loscocco G.G.; Fanelli A.; Para O.; Berni A.; Tassinari I.; Zammarchi L.; Maggi L.; Mazzoni A.; Scotti V.; Falchetti G.; Malandrino D.; Luise F.; Millotti G.; Bencini S.; Capone M.; Piccinni M.P.; Annunziato F.; Guglielmelli P.; Mannelli F.; Coltro G.; Fantoni D.; Borella M.; Ravenda E.; Peruzzi B.; Caporale R.; Cosmi L.; Liotta F.; Lombardelli L.; Logiodice F.; Vanni A.; Salvati L.; Lazzeri C.; Bonizzoli M.; Peris A.; Cianchi G.; Bosi A.; Pucatti M.; Fontanari P.; Benemei S.; MatucciCerinic M.; Turco L. | |
| Concomitant JAK2 mutated myeloproliferative neoplasms and hereditary hemochromatosis | 2022 | Loscocco, Giuseppe G; Santi, Raffaella; Carrai, Valentina; Coltro, Giacomo; Mannelli, Francesco; Guglielmelli, Paola; Vannucchi, Alessandro M |